CY1123060T1 - Μεθοδοι για τον καθορισμο των διαφορων στη δραστικοτητα της αλφα-4 ιντεγκρινης δια συσχετισμου των διαφορων στα επιπεδα svcam και/ή smadcam - Google Patents

Μεθοδοι για τον καθορισμο των διαφορων στη δραστικοτητα της αλφα-4 ιντεγκρινης δια συσχετισμου των διαφορων στα επιπεδα svcam και/ή smadcam

Info

Publication number
CY1123060T1
CY1123060T1 CY20201100555T CY201100555T CY1123060T1 CY 1123060 T1 CY1123060 T1 CY 1123060T1 CY 20201100555 T CY20201100555 T CY 20201100555T CY 201100555 T CY201100555 T CY 201100555T CY 1123060 T1 CY1123060 T1 CY 1123060T1
Authority
CY
Cyprus
Prior art keywords
differences
alpha
svcam
correlating
methods
Prior art date
Application number
CY20201100555T
Other languages
English (en)
Inventor
Alissa A. Chackerian
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1123060T1 publication Critical patent/CY1123060T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Παρέχεται εδώ μία μέθοδος παρακολούθησης της αλλαγής των δραστικοτήτων αλφα-4 ιντεγκρίνης σε ένα άτομο δια συσχέτισης με τα επίπεδα διαλυτού μορίου προσκόλλησης αγγειακών κυττάρων (sVCAM) και/ή διαλυτού μορίου βλεννογονικής αντρεσσίνης σε μόριο προσκόλλησης κυττάρων βλεννογονικής αντρεσσίνης (sMAdCAM). Συγκεκριμένα, η παρούσα μέθοδος μπορεί να χρησιμοποιηθεί, παραδείγματος χάριν, για την αξιολόγηση της φαρμακοκινητικής και της φαρμακοδυναμικής (PK/PD) ενός αναστολέα άλφα-4 ιντεγκρίνης που χρησιμοποιείται για τη θεραπεία μιας νόσος που σχετίζεται με παθολογική ή χρόνια φλεγμονή.
CY20201100555T 2010-10-25 2020-06-17 Μεθοδοι για τον καθορισμο των διαφορων στη δραστικοτητα της αλφα-4 ιντεγκρινης δια συσχετισμου των διαφορων στα επιπεδα svcam και/ή smadcam CY1123060T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40635810P 2010-10-25 2010-10-25
US40636510P 2010-10-25 2010-10-25
EP11838481.7A EP2632492B1 (en) 2010-10-25 2011-10-24 METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
PCT/US2011/057519 WO2012061074A1 (en) 2010-10-25 2011-10-24 METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Publications (1)

Publication Number Publication Date
CY1123060T1 true CY1123060T1 (el) 2021-10-29

Family

ID=46024768

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100555T CY1123060T1 (el) 2010-10-25 2020-06-17 Μεθοδοι για τον καθορισμο των διαφορων στη δραστικοτητα της αλφα-4 ιντεγκρινης δια συσχετισμου των διαφορων στα επιπεδα svcam και/ή smadcam

Country Status (17)

Country Link
US (3) US20130337470A1 (el)
EP (3) EP2632492B1 (el)
JP (2) JP5847188B2 (el)
AU (4) AU2011323820A1 (el)
CA (1) CA2816016A1 (el)
CY (1) CY1123060T1 (el)
DK (1) DK3326645T3 (el)
ES (2) ES2800066T3 (el)
HK (1) HK1256157A1 (el)
HR (1) HRP20200920T1 (el)
HU (1) HUE050713T2 (el)
LT (1) LT3326645T (el)
PL (1) PL3326645T3 (el)
PT (1) PT3326645T (el)
RS (1) RS60565B1 (el)
SI (1) SI3326645T1 (el)
WO (1) WO2012061074A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632492B1 (en) 2010-10-25 2017-10-04 Biogen MA Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
WO2016088068A1 (en) * 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994016094A2 (en) 1993-01-12 1994-07-21 Biogen, Inc. Recombinant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
BE1008817A6 (fr) 1994-10-28 1996-08-06 Univ Bruxelles Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
US5965356A (en) 1997-01-31 1999-10-12 University Of Maryland, Baltimore Herpes simplex virus type specific seroassay
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
CA2330000C (en) * 1998-05-13 2015-06-23 Genentech, Inc. Diagnosis and treatment of hepatic disorders
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
AP2002002565A0 (en) 1999-12-28 2002-06-30 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
CA2417432C (en) * 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
BR0307975A (pt) 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
SK50642005A3 (sk) 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
PT3417875T (pt) 2003-02-10 2020-08-24 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
NZ584288A (en) 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
CA2561164A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
WO2006096488A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
DK2645106T3 (en) * 2005-04-04 2017-10-02 Biogen Ma Inc Methods for Evaluating an Immune Response to a Therapeutic Agent
DK2676967T3 (da) 2006-02-28 2019-09-16 Biogen Ma Inc Fremgangsmåder til behandling af inflammatoriske og autoimmune sygdomme med natalizumab
MX2008011176A (es) 2006-03-03 2008-09-10 Elan Pharm Inc Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab.
EP2231185A4 (en) 2007-12-07 2012-06-27 Elan Pharm Inc METHOD AND COMPOSITIONS FOR TREATING LIQUID TUMORS
EP2279004B1 (en) * 2008-05-16 2015-01-14 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
WO2009141786A2 (en) 2008-05-21 2009-11-26 Piramal Life Sciences Limited Anti-inflammatory compounds
WO2010053316A2 (en) 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
AU2011245140A1 (en) * 2010-04-30 2012-12-20 Elan Pharmaceuticals, Inc. Selective integrin inhibitors
EP2632492B1 (en) 2010-10-25 2017-10-04 Biogen MA Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Also Published As

Publication number Publication date
HRP20200920T1 (hr) 2020-10-30
EP2632492A4 (en) 2014-04-02
WO2012061074A1 (en) 2012-05-10
EP2632492A1 (en) 2013-09-04
JP2014500950A (ja) 2014-01-16
EP3722808A1 (en) 2020-10-14
ES2800066T3 (es) 2020-12-23
HK1256157A1 (zh) 2019-09-13
LT3326645T (lt) 2020-08-10
CA2816016A1 (en) 2012-05-10
JP5847188B2 (ja) 2016-01-20
RS60565B1 (sr) 2020-08-31
AU2017201658B2 (en) 2019-03-21
EP2632492B1 (en) 2017-10-04
JP2015215363A (ja) 2015-12-03
AU2011323820A1 (en) 2013-05-23
AU2021212059A1 (en) 2021-08-26
SI3326645T1 (sl) 2020-09-30
EP3326645A1 (en) 2018-05-30
EP3326645B1 (en) 2020-03-18
AU2019204089A1 (en) 2019-07-04
HUE050713T2 (hu) 2020-12-28
US20160291035A1 (en) 2016-10-06
PT3326645T (pt) 2020-06-23
PL3326645T3 (pl) 2020-09-21
DK3326645T3 (da) 2020-06-15
AU2017201658A1 (en) 2017-03-30
US11079393B2 (en) 2021-08-03
US20130337470A1 (en) 2013-12-19
ES2654820T3 (es) 2018-02-15
US20220206012A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CY1120579T1 (el) Κυτταρα χρησιμα για προσδιορισμους δραστικοτητας αλλαντικης τοξινης οροτυπου α σε ανοσολογικη βαση
CY1123504T1 (el) Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων
CY1123060T1 (el) Μεθοδοι για τον καθορισμο των διαφορων στη δραστικοτητα της αλφα-4 ιντεγκρινης δια συσχετισμου των διαφορων στα επιπεδα svcam και/ή smadcam
ECSP13013036A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
BR112012012492A2 (pt) métodos para aumentar atividade de diidróxi ácido desidratase para aperfeiçoar produção de combustíveis, produtos químicos e aminoácidos
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
MX2018008324A (es) Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
CY1117948T1 (el) Μεθοδος επαγωγης ανοχης σε ενα αλλεργιογονο
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
EA201101053A1 (ru) Ингибиторы фосфоиноз итид-3-киназ с цинксвязывающей группой
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
UY34114A (es) Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
CL2012003385A1 (es) Tratamiento para la incontinencia.
NI201300013A (es) Análisis de biomarcadores para detectar o medir la inhibición de la actividad de la cinasa tor
AR089825A1 (es) Metodo para determinar la ubicacion, tamaño y condiciones in situ en un yacimiento de hidrocarburos con ecologia, geoquimica y grupos de biomarcadores
GB2535029A (en) Acoustic sensing system and method of acoustically monitoring a tool
TR201909787T4 (tr) Pelargonik asit ve flazasülfüron içeren herbisit kombinasyonu.
CY1122711T1 (el) Μεθοδος για την ενεργοποιηση και τη συζευξη βιομοριων
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
CY1124140T1 (el) Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης
CL2011002959A1 (es) Peptoide, metodo para identificar un ligando peptoide que es especificamente reconocido por las celulas autoinmunes; y su uso contre enfermedades autoinmune.
BR112016007251A2 (pt) método de processamento de biomassa que contém celulose
CL2014001658A1 (es) Un metodo y dispositivo para detectar y analizar depositos en un area de reflexion en particular dentro de un sistema que comprende liquido, donde el metodo comprende emitir una señal de emision ultrasonica hacia el area de reflexion, detectar una señal de reflexion ultrasonica obtenida por la reflexion, determinar una distribucion del tiempo de corrida de la señal de reflexion ultrasonica detectada y analizar la distribucion de modo tal de determinar si los depositos estan depositados
CY1120097T1 (el) Ναλμεφενη για τη μειωση της καταναλωσεως αλκοολης σε συγκεκριμενους πληθυσμους στοχους